The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. We supported key value-based strategic decisions with an ecosystem perspective.
Our client wished to design an ecosystem strategy for behavioural, drug and clinical health technologies that help at-risk obese persons to lose and maintain weight.
Our client - an EU 2.2bn global fiber-based materials company - was suffering from declining market share in its core surgical gowns and drapes market. To recover, it sensed growth potential in a new market segment characterised by particular types of surgical procedures.
Our client, a top 3 manufacturer of continence supplies, wished to formulate a North American ecosystem strategy for the larger institutional segment of its business.
A top 30 multi-national pharmaceutical wished to undertake an in-depth disease area strategy review to decide whether to reacquire the commercial rights to its currently out-licensed infection prevention and treatment technology.
We helped to establish the "listen and respond" approach to product innovation at Coloplast, a global Danish-based wound and skin care medical device company.
A global wound care company asked us to advise on the detailed nature of the ecosystem opportunity for a new diagnostic technology which sought to help healthcare practitioners, patients and consumers identify early indicators of wound infection at the point-of-care.
Our client wished to identify value-creation "hot spots" in European perinatal care ecosystems. With these hotspots identified, they then wished to identify and assess technology, drug and device assets that had the greatest potential to address them. With these identified and profiled, we supported our client to perform deeper dive assessments into target assets based on demand, impact, ecosystem and commercial value.
In 2008, ITI Scotland announced its wish to invest £7.9 Million over three and a half years in the development of advanced point of care wound infection diagnostic technology, specifically targeting diabetic foot ulcer wounds.